同仁堂回应“南极磷虾油产品”报道：四川健康药业不属于下属子企业

Core Viewpoint - Beijing Tongrentang Co., Ltd. issued a clarification announcement regarding misleading media reports about a product labeled as "99% high-purity Antarctic krill oil" linked to its brand, emphasizing that it does not hold any equity or investment rights in the involved distributor, Sichuan Health Pharmaceutical Co., Ltd. [1][6] Group 1: Company Response - The company has ordered Sichuan Health Pharmaceutical to cease distribution of the implicated product and initiated a full process review and traceability of the product [2] - Legal action has been initiated against the involved companies to protect consumer rights and the company's brand integrity [2][7] - The product in question was found to contain "0" krill oil, despite claims of high purity, leading to significant consumer deception [1][5] Group 2: Brand and Product Integrity - The packaging of the product misleadingly emphasized the "Beijing Tongrentang" name, creating confusion about its actual manufacturer [5] - The company clarified that it does not produce or authorize the production of the Antarctic krill oil product in question, and all its products are produced in-house [6][7] - The company has a diverse portfolio of over 400 traditional Chinese medicine products, which supports its brand development and operational stability [6] Group 3: Financial Performance - For Q3, the company reported revenue of 3.539 billion yuan, a year-on-year decline of 12.76%, with a net profit of 232 million yuan, down nearly 30% [7] - For the first three quarters, total revenue reached 13.308 billion yuan, a decrease of 3.7%, with a net profit of 1.178 billion yuan, down 12.78% [7] - As of December 17, the company's stock price closed at 32.57 yuan, down 0.82% [8]